Alto Neuroscience (NYSE:ANRO) Hits New 12-Month High – Here’s Why

Alto Neuroscience, Inc. (NYSE:ANRO) hit a new 52-week high on Thursday . The company traded as high as $29.49 and last traded at $29.1860, with a volume of 94860 shares. The stock had previously closed at $28.03.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ANRO shares. Wall Street Zen lowered Alto Neuroscience from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. Chardan Capital reiterated a “buy” rating and set a $30.00 target price on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Finally, Wedbush increased their price target on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Price Performance

The business has a fifty day moving average price of $24.87 and a 200-day moving average price of $22.29. The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $1.00 billion, a PE ratio of -11.82 and a beta of 1.06.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). Research analysts expect that Alto Neuroscience, Inc. will post -3.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds have recently made changes to their positions in the business. Quantinno Capital Management LP grew its stake in shares of Alto Neuroscience by 1.4% during the first quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock valued at $811,000 after buying an additional 490 shares during the last quarter. Torren Management LLC bought a new stake in shares of Alto Neuroscience in the 4th quarter valued at about $62,000. XTX Topco Ltd lifted its stake in shares of Alto Neuroscience by 32.2% in the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock valued at $371,000 after acquiring an additional 5,078 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Alto Neuroscience by 6.3% during the 1st quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock valued at $2,327,000 after acquiring an additional 6,100 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Alto Neuroscience by 26.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company’s stock valued at $884,000 after acquiring an additional 8,148 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.